IGF-1 LR3: Structure, Binding-Protein Affinity and Receptor Pharmacology

IGF-1 LR3 carries the full 70-residue human IGF-1 chain with two engineered changes: arginine replaces glutamate at position 3, and a 13-residue extension, MFPAMPLSSLFVN, is fused to the N-terminus. The result is an 83-residue single chain of 9111.45 g/mol, about 19 percent heavier than the roughly 7.65 kDa parent hormone.

Folding is unchanged from the parent. Six cysteines close three intrachain bridges, Cys6-Cys48, Cys18-Cys61 and Cys47-Cys52 in IGF-I numbering, so the B, C, A and D domain arrangement that presents the receptor-contact surface survives the modifications. The extension peptide adds no cysteine and no glycosylation site. Two molecular formulas appear in supplier catalogues, C400H619N111O115S9 at 9111.45 g/mol and C400H625N111O115S9 at 9117.60 g/mol; the difference of six hydrogens is precisely the oxidised versus reduced state of those three bridges.

The extension is a fossil of how the molecule was made. An Adelaide group expressing IGF-I in Escherichia coli fused the hormone to N-terminal sequence from porcine growth hormone with a hydroxylamine-cleavable linker, then found that leaving the extension attached, combined with the Glu3 substitution, produced a markedly more potent species in cell assays. What began as a purification handle became the product.

IGF-1 LR3 binds the six IGF-binding proteins roughly 689-fold more weakly than IGF-I in competition assays against L6 myoblast-conditioned medium, and reagent documentation for LONG R3 IGF-I quotes a greater than 1000-fold reduction. Because IGFBP-3 normally sequesters most circulating IGF-I in a ternary complex, that loss of affinity is the analogue's defining property.

Two structural facts explain it. The first three residues of IGF-I, Gly-Pro-Glu, sit at the binding-protein interface, and the acidic Glu3 side chain contributes directly; removing that tripeptide altogether yields Des(1-3)-IGF-I, which shows the same shift, while swapping Glu3 for the basic arginine yields R3-IGF-I. The second contribution is steric: the 13-residue extension adds bulk immediately adjacent to that interface. Combining both edits is what pushes the reduction into the several-hundred-fold range.

The functional consequence is a shift in the free fraction. In culture medium containing binding proteins secreted by the cells themselves, far more of the added analogue remains unbound and available to the receptor, which is why the material is described as roughly three times as potent as IGF-I in vitro. Reagent specifications quote an ED50 below 10 ng/mL in an L6 myoblast protein-synthesis assay, corresponding to a specific activity near 100,000 units per milligram.

IGF-1 LR3 acts as a full agonist at the type 1 IGF receptor, a disulfide-linked (αβ)2 receptor tyrosine kinase. Cryo-EM work on IGF1R describes a Γ-shaped asymmetric dimer in which a single ligand bridges the L1 and CR domains of one protomer and the α-CT and FnIII-1 domains of the other, with an L1-FnIII-2 contact holding the membrane-proximal region together.

Affinity at that site is modestly lower for the analogue than for the parent, about 3.2-fold, so the potency gain is not receptor-driven. Occupancy triggers trans-autophosphorylation of the intracellular kinase domains, recruitment of IRS-1 and SHC, and signalling through PI3K-AKT and RAS-ERK. In the liganded receptor the two α-CT segments form a rigid beam that obstructs the conformational change a second ligand would need, which is the structural account of the negative cooperativity long observed in binding data.

The reduced binding-protein affinity does not make the analogue immune to regulation. Work on IGF1R phosphorylation showed that recombinant IGFBP-3 inhibited receptor phosphorylation induced by IGF-I, IGF-II, Des(1-3)IGF-I and Long(R3)IGF-I across a similar concentration range, attributing the effect to sequestration in the extracellular compartment. Reagent literature also notes that the modified molecule still engages the insulin receptor, so selectivity between the two closely related kinases is relative rather than absolute.

IGF-1 LR3 is supplied as a serum-free culture supplement for Chinese hamster ovary and other mammalian lines, where it substitutes for insulin. Manufacturer documentation describes it as roughly 200 times more potent than insulin in culture and about twice as stable, with reported gains of up to 62 percent in volumetric productivity over unsupplemented CHO culture.

The same documentation puts the margin over insulin-supplemented culture at 40 percent, and independent bioprocess reports back the general direction. A comparison of insulin against LongR3 in two serum-free CHO lines expressing recombinant proteins found the analogue sustained viability better under production conditions. A CHO41K microarray study reported enhanced expansion and delayed cell death with LongR3, and read the transcriptome as showing reduced cellular investment in cytoskeletal assembly. A separate industrial study of an Fc-fusion line reported higher sialic acid content and a lower proportion of asialylated N-linked glycans with LongR3 present at microgram-per-litre levels, making glycan quality, not only titre, part of the argument.

Supply economics shape the interest. Escherichia coli inclusion-body expression remains standard, and a 2023 report fused both IGF-1 and LR3 IGF-1 to xylanase for secretion from Pichia pastoris, reaching roughly 0.5 g/L and 1 g/L respectively in bioreactor fermentation with bioactivity matching a reference IGF-1. Reviews of serum-free media for cultivated meat identify recombinant growth factors as a dominant media cost, which keeps yield and purification work on this class of protein active.

IGF-1 LR3 has been infused into late-gestation fetal sheep across several published studies. A 90-minute infusion lowered fetal plasma insulin, and insulin concentrations measured during a hyperglycaemic clamp ran 66 percent below vehicle controls, yet islets isolated afterwards secreted insulin normally, pointing to a reversible effect rather than an intrinsic islet defect.

The same model produced a negative result at one week. In growth-restricted late-gestation fetal sheep, a week-long infusion did not increase growth relative to vehicle, circulating amino acids fell with branched-chain species most affected, and insulin concentrations along with glucose-stimulated secretion were unchanged between groups. Earlier work in normally grown fetal sheep had reported organ-specific responses without increased nutrient transfer across the placenta, so the effect is model-dependent and not uniformly anabolic.

Recent work has explored delivery from materials rather than systemic exposure. A 2025 conduit study combined a decellularised Alstroemeria stem scaffold with GelMA and controlled IGF-1 LR3 release across a 1 cm rat sciatic nerve defect, reporting axonal regeneration comparable to autologous nerve graft controls on gait, electrophysiology and histology without systemic toxicity. A 2026 rat study loaded IGF1-LR3 into a poly(ethylene glycol)-acrylate void filler for volumetric muscle loss and found higher wet weight of the affected muscle at 28 days but no gain in isometric torque or histological markers.

Central-nervous-system exposure has also been examined. Male 5XFAD transgenic mice given intranasal LR3-IGF-1 for seven months showed remodelled cortical amyloid, with fewer filamentous plaques and a larger inert plaque fraction, while behavioural testing detected no preservation of cognitive function. The authors framed the compound as a candidate component of combination approaches rather than as a standalone intervention.

IGF-1 LR3 is identified by immunoaffinity capture followed by liquid chromatography and high-resolution tandem mass spectrometry, which separates it from IGF-I, R3-IGF-I and Des(1-3)-IGF-I on intact mass and on characteristic proteolytic fragments. Anti-doping laboratories run the same workflow because IGF-1 and its analogues sit in the WADA prohibited class, banned at all times.

A 2021 method development study characterised all three analogues and their degradation products, and reported that market-sourced material carried abundant oxidised peptide forms. In rats, after delivery into skeletal muscle, Des(1-3)-IGF-I and R3-IGF-I remained detectable to 24 hours while the LongR3 signal disappeared after roughly 4 hours. That short window makes retrospective identification in a biological matrix considerably harder for this analogue than for its shorter cousins.

Product-identity work has turned up material that does not match its label. Mass spectrometry on the contents of one market vial identified a His-tagged Long-R3-IGF-I bearing a C-terminal hexahistidine tag, a construct made for biochemical assays rather than for any other purpose. On the urine side, a 2024 method covering peptidic analytes between 2 and 10 kDa reported long-R3-IGF-I, R3-IGF-I and des1-3-IGF-I among its target list and met the minimum required performance levels for initial testing procedures. In bioprocess settings, immunoassays specific to LONG R3 IGF-I are used instead, to track carry-over of the supplement through downstream purification of the expressed product.

IGF-1 LR3 is distributed as a sterile-filtered lyophilised powder, typically from a dilute phosphate buffer near pH 7.2, at 98 percent or greater purity by SDS-PAGE and reversed-phase HPLC. Supplier documentation specifies desiccated storage below minus 18 degrees Celsius, with the sealed vial kept dry and brought to ambient temperature before opening.

Published preparation notes describe dissolving the lyophilisate in sterile 18 megohm-centimetre water at around 100 micrograms per millilitre. Working solutions below that concentration are commonly carried in a buffer containing a carrier protein, because dilute solutions of a 9 kDa protein lose material to container surfaces. Documented stability for the redissolved stock is two to seven days at 4 degrees Celsius, or below minus 18 degrees Celsius for longer periods, with aliquoting used to avoid repeated freeze-thaw cycles.

Two chemistry constraints follow from the structure. Three disulfide bridges mean reducing agents change the molecular identity and the measured mass by six hydrogens, so reduced and oxidised forms should not be treated as interchangeable in analytical work. Methionine oxidation is the reported degradation signature in poorly stored material, which makes intact-mass confirmation worth running alongside a purity gel. Material of this class is supplied for laboratory research use only and is not for human or veterinary use.